Immunotherapy drug tested for rare, Tough-to-Treat cancers
NCT ID NCT03316573
First seen Jan 10, 2026 · Last updated Apr 30, 2026 · Updated 17 times
Summary
This study tested the drug pembrolizumab (Keytruda) in 18 people with aggressive lymphomas or rare immune cell cancers that had come back or not responded to other treatments. The goal was to see if the drug could shrink tumors. The study is currently on hold.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
University of Nebraska
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.